Skip to main content
SpringerLink
Log in

Brustkrebs: MET+, CD47+ – Prognose düster

  • Literatur kompakt_Mammakarzinom und gynäkologische Tumoren
  • Published:
Im Focus Onkologie Aims and scope

Sind in Mammakarzinomen des Luminaltyps die Marker MET und CD47 nachweisbar, spricht das für eine schlechte Prognose: Die Patientinnen leben im Schnitt rund zehn Jahre kürzer als Frauen, deren Tumoren für MET und CD47 negativ sind.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Baccelli I et al. Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients. Oncotarget. 2014; 5(18):8147-60.

    PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Robert Bublak

Authors
  1. Robert Bublak
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bublak, R. Brustkrebs: MET+, CD47+ – Prognose düster. Im Focus Onkologie 17, 30 (2014). https://doi.org/10.1007/s15015-014-1495-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-014-1495-1

Search

Navigation